The present study aimed to identify the risk of BM worsening in patients with EGFR‐positive NSCLC treated with osimertinib, specifically to evaluate the impact of osimertinib dose reduction on BM control. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.